Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression

Scott D. Holmberg*, Merle E. Hamburger, Anne C. Moorman, Kathy C. Wood, Frank J. Palella

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


To analyze factors associated with long-term (≥2 years) suppression of virus load (VL), we performed a nested case-control analysis of 1235 Human Immunodeficiency Virus Outpatient Study cohort participants who were well characterized by multiple VL and CD4+ cell count determinations. Of these patients, 286 (23.1%) had maintained undetectable VLs (i.e., >400 copies/mm3 or >50 copies/mm3) for ≥2 years. Being treatment naive at the start of antiretroviral therapy was associated with a greater likelihood of achieving long-term suppression of VL (odds ratio [OR], 1.5; 95% confidence interval, 1.0-2.0; P = .028). In multivariate models, abacavir, indinavir, efavirenz, and drug combinations that included both lamivudine and indinavir were the most effective treatments for achieving long-term suppression of VL (adjusted OR for each, >3.6; P value for each, <.01). Long-term suppression of VL is more likely in treatment-naive than in treatment-experienced patients, but there were several drugs - abacavir, efavirenz, indinavir, and drug combinations including lamivudine and indinavir - that appeared to be effective, whether they were part of a first or subsequent drug regimen.

Original languageEnglish (US)
Pages (from-to)702-707
Number of pages6
JournalClinical Infectious Diseases
Issue number5
StatePublished - Sep 1 2003

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Factors associated with maintenance of long-term plasma human immunodeficiency virus RNA suppression'. Together they form a unique fingerprint.

Cite this